Voted in the World’s Top 10 Most Influential Ophthalmologists in April 2023. Read more here

Professor Gazzard was recently promoted to Director of Surgery at Moorfields Eye Hospital

He has joined the Glaucoma Research Society as one of the top 100 glaucoma researchers in the field

Part of the world’s first randomised controlled trial to prove the effectiveness of the PRESERFLO™ MicroShunt Glaucoma Drainage System. Read more

Has the largest amount of experience in the U.K. and Europe with Hydrus micro-stent procedures, with over 350 devices implanted. Read more

Is a leading author of multiple publications on Minimally Invasive Glaucoma Surgery (MIGS) including influential Cochrane meta-analyses of all the available studies Read more

Led the world’s largest, pivotal and highly influential study proving laser can be safely and effectively used for newly diagnosed open angle glaucoma patients as in the ground-breaking Selective Laser Trabeculoplasty (SLT) study. Read more

Let There Be (Laser) Light article in the Ophthalmologist cites Gazzard’s work as the European Glaucoma Society Guidelines Committee changes recommendations for the initial treatment of open angle glaucoma. You can read the full article in The Ophthalmologist here.

He has been appointed Visiting Professor at NYU (Langone Health) – New York University.

Read the Latest News and press about Professor Gus Gazzard and his work here

Find out more about Professor Gazzard’s background and experience. Read more